Logo image of APS.CA

APTOSE BIOSCIENCES INC (APS.CA) Stock Fundamental Analysis

Canada - TSX:APS - CA03835T4081 - Common Stock

1.76 CAD
+0.02 (+1.15%)
Last: 10/24/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to APS. APS was compared to 21 industry peers in the Biotechnology industry. Both the profitability and financial health of APS have multiple concerns. APS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APS had negative earnings in the past year.
In the past year APS has reported a negative cash flow from operations.
APS had negative earnings in each of the past 5 years.
APS had a negative operating cash flow in each of the past 5 years.
APS.CA Yearly Net Income VS EBIT VS OCF VS FCFAPS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

APS has a worse Return On Assets (-327.57%) than 66.67% of its industry peers.
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROIC N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APS.CA Yearly ROA, ROE, ROICAPS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

APS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APS.CA Yearly Profit, Operating, Gross MarginsAPS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

APS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APS.CA Yearly Shares OutstandingAPS.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50K 100K 150K 200K 250K
APS.CA Yearly Total Debt VS Total AssetsAPS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -79.88, we must say that APS is in the distress zone and has some risk of bankruptcy.
APS has a Altman-Z score of -79.88. This is in the lower half of the industry: APS underperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -79.88
ROIC/WACCN/A
WACCN/A
APS.CA Yearly LT Debt VS Equity VS FCFAPS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

APS has a Current Ratio of 1.05. This is a normal value and indicates that APS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of APS (1.05) is comparable to the rest of the industry.
A Quick Ratio of 1.05 indicates that APS should not have too much problems paying its short term obligations.
APS has a Quick ratio (1.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05
APS.CA Yearly Current Assets VS Current LiabilitesAPS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.60% over the past year.
EPS 1Y (TTM)79.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, APS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.27%
EPS Next 2Y40.08%
EPS Next 3Y26.19%
EPS Next 5Y16.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APS.CA Yearly Revenue VS EstimatesAPS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M 400M 500M
APS.CA Yearly EPS VS EstimatesAPS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100 -200 -300 -400 -500

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APS. In the last year negative earnings were reported.
Also next year APS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APS.CA Price Earnings VS Forward Price EarningsAPS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APS.CA Per share dataAPS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60

4.3 Compensation for Growth

APS's earnings are expected to grow with 26.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.08%
EPS Next 3Y26.19%

More info and screens

0

5. Dividend

5.1 Amount

APS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTOSE BIOSCIENCES INC

TSX:APS (10/24/2025, 7:00:00 PM)

1.76

+0.02 (+1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners0.99%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap4.49M
Revenue(TTM)N/A
Net Income(TTM)-35800000
Analysts82.86
Price Target136.76 (7670.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.9%
Min EPS beat(2)64.27%
Max EPS beat(2)69.52%
EPS beat(4)4
Avg EPS beat(4)37.14%
Min EPS beat(4)3.29%
Max EPS beat(4)69.52%
EPS beat(8)6
Avg EPS beat(8)16.09%
EPS beat(12)9
Avg EPS beat(12)10.77%
EPS beat(16)12
Avg EPS beat(16)11.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-66.25
EYN/A
EPS(NY)-3.13
Fwd EYN/A
FCF(TTM)-20.45
FCFYN/A
OCF(TTM)-20.45
OCFYN/A
SpS0
BVpS-5.02
TBVpS-5.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z -79.88
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.76%
Cap/Depr(5y)62.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.91%
EPS Next Y95.27%
EPS Next 2Y40.08%
EPS Next 3Y26.19%
EPS Next 5Y16.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.1%
EBIT Next 3Y11.61%
EBIT Next 5YN/A
FCF growth 1Y6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.39%
OCF growth 3YN/A
OCF growth 5YN/A

APTOSE BIOSCIENCES INC / APS.CA FAQ

What is the ChartMill fundamental rating of APTOSE BIOSCIENCES INC (APS.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to APS.CA.


What is the valuation status for APS stock?

ChartMill assigns a valuation rating of 1 / 10 to APTOSE BIOSCIENCES INC (APS.CA). This can be considered as Overvalued.


Can you provide the profitability details for APTOSE BIOSCIENCES INC?

APTOSE BIOSCIENCES INC (APS.CA) has a profitability rating of 0 / 10.